TRANSTHERA-B (02617) announced that Neurocrine Biosciences, Inc. (NASDAQ: NBIX) has entered into a royalty-bearing patent transfer and research collaboration agreement with the company to develop NLRP3 inhibitors for treating various diseases (the Agreement). Under the Agreement, Neurocrine is granted exclusive rights to develop, manufacture, and commercialize NLRP3 inhibitors from TRANSTHERA’s NLRP3 drug platform outside Greater China, while the company retains rights for development, manufacturing, and commercialization within Greater China (Mainland China, Hong Kong, Taiwan, and Macau).

The company is entitled to receive an upfront payment and may receive additional milestone payments tied to Neurocrine’s development and commercialization progress, including R&D and sales milestones. The total potential value of the Agreement is $881.5 million. The Agreement also includes a research collaboration between the parties to further advance NLRP3-related technologies.